~ Buy the SUPPRELIN LA (histrelin acetate) Drug Profile, 2024 PDF Report in the Report Store ~

SUPPRELIN LA Drug Patent Profile

✉ Email this page to a colleague

When do Supprelin La patents expire, and when can generic versions of Supprelin La launch?

Supprelin La is a drug marketed by Endo Operations and is included in one NDA. There is one patent protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Supprelin La

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 16, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SUPPRELIN LA?
What are the global sales for SUPPRELIN LA?
What is Average Wholesale Price for SUPPRELIN LA?

Summary for SUPPRELIN LA

International Patents:	3
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	2
Patent Applications:	893
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for SUPPRELIN LA
DailyMed Link:	SUPPRELIN LA at DailyMed

Drug patent expirations by year for SUPPRELIN LA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SUPPRELIN LA

Generic Entry Date for SUPPRELIN LA^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 022058 Dosage: IMPLANT;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SUPPRELIN LA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southwest Oncology Group	Phase 3
National Cancer Institute (NCI)	Phase 3
University of Colorado, Denver	Phase 2

See all SUPPRELIN LA clinical trials

Pharmacology for SUPPRELIN LA

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

US Patents and Regulatory Information for SUPPRELIN LA

SUPPRELIN LA is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SUPPRELIN LA is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SUPPRELIN LA

Compositions and methods for treating precocious puberty
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SUPPRELIN LA

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007	⤷ Sign Up	⤷ Sign Up
Endo Operations	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SUPPRELIN LA

See the table below for patents covering SUPPRELIN LA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	1018392		⤷ Sign Up
Austria	149345		⤷ Sign Up
Denmark	0551698		⤷ Sign Up
European Patent Office	0551698	Fabrication d'articles hydrophiles hydro-gonflables et dispositifs de délivrance de médicaments (Manufacture of water - swellable hydrophilic articles and drug delivery devices)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration